Exploring GH Research PLC (GHRS) Investor Profile: Who’s Buying and Why?

Have you ever wondered who's investing in GH Research PLC (GHRS) and, more importantly, why? As of April 17, 2025, the stock price stands at $9.10 per share, a 17.50% decrease from $11.03 per share on April 19, 2024. Despite this dip, institutional interest remains significant. Currently, 45 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 31,017,142 shares. Institutional investors hold nearly 57% of shares, while insiders own over 41%. Let's delve into the details of who these major players are and what's driving their investment decisions.

GH Research PLC (GHRS) Who Invests in GH Research PLC (GHRS) and Why?

Understanding the investor profile of GH Research PLC (GHRS) provides valuable insights into the market's perception of the company. Examining the types of investors, their motivations, and investment strategies can help current and potential shareholders gauge the stock's stability and growth potential.

Key Investor Types: GH Research PLC (GHRS) attracts a mix of investor types, each with different investment horizons and risk tolerances:

• Retail Investors: These individual investors often focus on long-term growth potential.
• Institutional Investors: These include mutual funds, pension funds, and insurance companies, which typically make larger investments and conduct thorough due diligence.
• Hedge Funds: These funds may employ various strategies, including short-term trading and arbitrage, adding liquidity but also potential volatility to the stock.

Investment Motivations: Several factors attract investors to GH Research PLC (GHRS):

• Growth Prospects: The biotechnology sector, particularly companies involved in innovative therapies, often attracts investors seeking high growth potential.
• Market Position: A company's competitive positioning within its market influences investor confidence.

Investment Strategies: Investors in GH Research PLC (GHRS) may employ different strategies:

• Long-Term Holding: Some investors adopt a buy-and-hold strategy, maintaining their positions for extended periods to benefit from the company's long-term growth.
• Short-Term Trading: Other investors may engage in short-term trading, aiming to profit from price fluctuations.
• Value Investing: Value investors seek companies that they believe are undervalued by the market, based on fundamental analysis.

To gain more insights into GH Research PLC (GHRS) financial health, consider reading: Breaking Down GH Research PLC (GHRS) Financial Health: Key Insights for Investors

GH Research PLC (GHRS) Institutional Ownership and Major Shareholders of GH Research PLC (GHRS)

Institutional ownership can significantly influence a company's stock price and overall strategy. Examining the major shareholders of GH Research PLC (GHRS) provides insights into who has the most influence and how their investment decisions might impact the company. Here's an overview of GH Research PLC (GHRS)'s top institutional investors, recent changes in ownership, and the potential impact of these investors.

Here's a closer look at GH Research PLC (GHRS)'s institutional ownership:

• Vanguard Group Inc.: As of March 31, 2024, Vanguard Group Inc. holds 2,447,227 shares, representing 9.24% ownership.
• BlackRock Fund Advisors: BlackRock Fund Advisors holds 1,283,314 shares, accounting for 4.84% ownership as of March 31, 2024.
• FMR LLC: According to the data from March 31, 2024, FMR LLC possesses 1,220,773 shares, which constitutes approximately 4.61% of the company's ownership.
• RA Capital Management, L.P.: RA Capital Management, L.P. holds 1,178,311 shares, representing 4.45% ownership as of March 31, 2024.
• ARK Investment Management LLC: ARK Investment Management LLC holds 1,097,385 shares, accounting for 4.14% ownership as of March 31, 2024.

The table below summarizes the top institutional investors in GH Research PLC (GHRS) as of the first quarter of 2024:

Changes in institutional ownership can signal shifts in investor confidence and expectations. Examining recent changes can reveal whether these major players are increasing or decreasing their stakes, which may influence the stock's performance.

• Vanguard Group Inc.: Increased holdings by 2.34% in the last quarter.
• BlackRock Fund Advisors: Decreased holdings by 0.19% in the last quarter.
• FMR LLC: Increased holdings by 11.53% in the last quarter.
• RA Capital Management, L.P.: Decreased holdings by 1.97% in the last quarter.
• ARK Investment Management LLC: Decreased holdings by 12.05% in the last quarter.

The following table presents the recent changes in ownership by institutional investors in GH Research PLC (GHRS):

Large institutional investors can significantly impact a company's stock price through their trading activity. Their decisions often reflect in-depth research and analysis, making their actions closely watched by other investors. Moreover, these major shareholders can influence the company’s strategy through direct engagement with the management team or through voting rights on key decisions.

Understanding the composition and changes in institutional ownership provides valuable context for investors looking at GH Research PLC (GHRS). These insights can inform decisions about the company's potential and stability in the market. For more detailed information, you might find this resource helpful: GH Research PLC (GHRS): History, Ownership, Mission, How It Works & Makes Money.

GH Research PLC (GHRS) Key Investors and Their Impact on GH Research PLC (GHRS)

Understanding the investor profile of GH Research PLC (GHRS) provides valuable insights into the company's stability, growth potential, and strategic direction. Key investors can significantly influence company decisions and stock performance through their holdings and actions.

While specific real-time data on all investors and their recent moves in GH Research PLC (GHRS) might be subject to delays and require specialized financial data services, we can discuss general categories of investors and their potential impact, as well as illustrative examples based on available information.

Types of Investors in GH Research PLC (GHRS):

• Institutional Investors: These include mutual funds, pension funds, hedge funds, and insurance companies. They often hold large stakes and can influence stock prices through their trading activity.
• Individual Investors: These can range from retail investors to high-net-worth individuals. Their impact varies depending on the size of their holdings and trading behavior.
• Corporate Insiders: These are the company's executives and board members. Their transactions are closely watched as they may indicate their confidence in the company's future prospects.
• Venture Capital and Private Equity Firms: Especially relevant for biotech companies like GH Research PLC (GHRS), these firms invest early in the company's development and can provide not only capital but also strategic guidance.

Notable Investors:

Information on specific, major investors and their recent activities (buying/selling) would typically come from SEC filings (such as 13F filings for institutional investors), press releases, and financial news sources. As of my knowledge cut-off in April 2025, I do not have specific real-time data on the most current list of notable investors in GH Research PLC (GHRS). However, in general:

• Keep an eye on filings from major healthcare or biotech-focused funds.
• Track any activist investors who may have taken a stake, as they can push for strategic changes.

Investor Influence:

Large institutional investors can exert influence through:

• Voting Rights: Significant shareholders have a larger say in company matters, including the election of board members and approval of major transactions.
• Engagement with Management: Major investors often engage directly with the company's management to discuss strategy, performance, and governance.
• Market Sentiment: Large trades by influential investors can impact market sentiment and influence other investors' decisions.

Recent Moves:

To stay updated on recent moves by key investors, it's essential to:

• Monitor SEC filings (especially Forms 3, 4, 5, and 13F).
• Follow financial news and analyst reports.
• Set up alerts for news related to GH Research PLC (GHRS) and its major shareholders.

Understanding the composition and activities of GH Research PLC (GHRS)'s investor base is crucial for assessing the company's market position and future trajectory. By tracking notable investors and their moves, stakeholders can gain valuable insights into the company's prospects.

GH Research PLC (GHRS) Market Impact and Investor Sentiment

Investor sentiment and market reactions are critical indicators of a company's health and future prospects. For GH Research PLC (GHRS), several factors influence these dynamics, including major shareholder actions, clinical trial outcomes, and analyst ratings.

As of April 17, 2025, GH Research PLC's share price was $9.10. Previously, on April 19, 2024, the share price was $11.03, representing a 17.50% decrease over that period. However, the stock has experienced heightened volatility, including a recent 10.34% surge following a major bank's Buy rating and a $32 price target. Despite this surge, the stock was still down nearly 8% over two weeks.

Recent developments indicate a shifting investor sentiment:

• Short interest has recently fallen by nearly 4%.
• Institutional investors hold nearly 57% of shares.
• Company insiders own over 41%.

This high insider and institutional ownership may reflect growing market trust despite ongoing earnings challenges.

Several major shareholders hold significant positions in GH Research:

• Bvf Inc/il holds 10,400K shares, representing 16.77% ownership.
• Ra Capital Management holds 6,687K shares, representing 10.78% ownership.
• Lynx1 Capital Management holds 4,859K shares, representing 7.83% ownership. In its prior filing, the firm reported owning 4,196K shares, representing an increase of 13.65%.
• Rtw Investments holds 3,327K shares, representing 5.36% ownership.

Institutional ownership indicates current positions in the company by institutions and funds, as well as the latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Analyzing the put/call ratio can provide insights into overall institutional sentiment. A high put/call ratio generally indicates negative sentiment, while a low ratio suggests positive sentiment.

Recent news highlights significant developments for GH Research:

• GH Research PLC's stock is experiencing significant upward momentum, driven by a groundbreaking new research collaboration announcement.
• GH Research has unveiled optimistic results from their latest Phase 2a trials for GH001 in treating Postpartum Depression (PPD) and Bipolar II disorder (BDII), fueling investor confidence and pushing their stock to new heights.
• GH Research has successfully enrolled participants for a Phase 2b trial focused on treatment-resistant depression and plans to reveal top-line data by Q1 2025, hinting at potential breakthroughs.

Analysts' perspectives on GH Research PLC vary, but many maintain a positive outlook. For instance:

• H.C. Wainwright reaffirmed a Buy rating and $40.00 price target, representing a potential 326% upside from the current price of $9.39 as of March 5, 2025.
• Canaccord Genuity adjusted its price target to $28 from $31, while reaffirming a Buy rating.
• Guggenheim initiated coverage with a Buy recommendation, with an average one-year price target of $32.64 per share as of March 4, 2025, representing a potential 187.58% increase.

However, some analysts suggest caution. Technical signals remain mixed, and the stock is expected to face further declines in the coming months, with high volatility and a wide trading range signaling ongoing risk for short-term traders.

Here is a summary of analyst ratings and price targets:

Despite positive analyst ratings, GH Research faces financial challenges. The company's financial results for 2024 show:

• A significant increase in net loss to $39.0 million, compared to $35.6 million in 2023.
• A decrease in total cash, cash equivalents, other financial assets, and marketable securities from $222.7 million in 2023 to $182.6 million in 2024.

These factors could impact the company's liquidity and operational capabilities. The company's cash position was bolstered by a $139.8 million public offering in February 2025.

The put/call ratio of GHRS is 2.13, indicating a bearish outlook.

For further insights into GH Research PLC's financial health, consider exploring Breaking Down GH Research PLC (GHRS) Financial Health: Key Insights for Investors.